ImmunoPrecise Antibodies Ltd. (IPA)
NASDAQ: IPA · Real-Time Price · USD
0.386
-0.017 (-4.22%)
Feb 21, 2025, 4:00 PM EST - Market closed
ImmunoPrecise Antibodies Employees
As of April 30, 2024, ImmunoPrecise Antibodies had 101 total employees, including 72 full-time and 29 part-time employees. The number of employees decreased by 1 or -0.98% compared to the previous year.
Employees
101
Change (1Y)
-1
Growth (1Y)
-0.98%
Revenue / Employee
$171,013
Profits / Employee
-$198,247
Market Cap
12.95M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Apr 30, 2024 | 101 | -1 | -0.98% |
| Apr 30, 2023 | 102 | 17 | 20.00% |
| Apr 30, 2022 | 85 | 12 | 16.44% |
| Apr 30, 2021 | 73 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
IPA News
- 2 days ago - ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period - Business Wire
- 26 days ago - ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture - Business Wire
- 4 weeks ago - IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment - Business Wire
- 5 weeks ago - ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation - Business Wire
- 7 weeks ago - IPA Announces Resignation of Chief Financial Officer - Business Wire
- 7 weeks ago - $116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors - Business Wire
- 2 months ago - ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases - Business Wire
- 2 months ago - IPA to Present at The Microcap Conference 2025 - Accesswire